Company
UNDERDOG
Treating the Underlying Causes of Age-Related Disease
Also known as Cyclarity Therapeutics, Cyclarity Therapeutics, Inc.
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
- Legal name
- Cyclarity Therapeutics, Inc.
- underdogpharma.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Cyclarity Pharmaceuticals, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting toxic forms of cholesterol, using rationally designed molecules, to provide the first true disease-modifying treatments for age-related diseases such as atherosclerosis, hypercholesterolemia, heart failure, and macular degeneration.
Funding snapshot
- Total raised
- $15.3MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Seed extension, $10M2021-08
Funding rounds
- Round, 2024
- $10.3M2024-12-16, SEC form D sold, 19 investors
- Round, 2021
- $3.5M2021-08-24, SEC form D sold, 10 investors
- Seed extension
- $10M2021-08, Company stated
- Round, 2019
- $1.5M2019-11-12, SEC form D sold, 9 investors
- Seed
- $4M2019-11, Company stated
Products
- Other
- UDP-003
Loading relationship preview